State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
The First Affiliated Hospital of Zhejiang, Chinese Medical University, Hangzhou, 310006, China.
Med Oncol. 2023 Jun 22;40(7):211. doi: 10.1007/s12032-023-02069-8.
Traditional Chinese medicine (TCM) has been widely used for cancer treatment. Identification of anti-cancer targets of TCM is the first and principal step in discovering molecular mechanisms of TCM as well as obtaining novel targets for cancer therapy. In this study, glycogen phosphorylase L (PYGL) was identified as one of the targeted proteins for several TCMs and was upregulated in various cancer types. The expression level of PYGL was positively correlated with the stage of lung cancer and the poor prognosis of patients. Meanwhile, knockdown of PYGL significantly inhibited proliferation and migration in lung cancer cells. In addition, PYGL was associated with spindle, kinetochore, and microtubule, the cellular components that are closely related to mitosis, in lung cancer. Moreover, PYGL was more susceptible to be upregulated by 144 mutated genes. Taken together, PYGL is a potential target for lung cancer treatment and its molecular mechanism probably influences the mitotic function of cells by regulating energy metabolism.
传统中药（TCM）已被广泛用于癌症治疗。鉴定 TCM 的抗癌靶点是发现 TCM 分子机制以及获得癌症治疗新靶点的第一步和主要步骤。在这项研究中，糖原磷酸化酶 L（PYGL）被鉴定为几种 TCM 的靶向蛋白之一，并且在各种癌症类型中上调。PYGL 的表达水平与肺癌的阶段和患者的不良预后呈正相关。同时，PYGL 的敲低显著抑制了肺癌细胞的增殖和迁移。此外，PYGL 与肺癌中与有丝分裂密切相关的纺锤体、着丝粒和微管相关。此外，144 个突变基因更容易使 PYGL 上调。总之，PYGL 是肺癌治疗的一个潜在靶点，其分子机制可能通过调节能量代谢来影响细胞的有丝分裂功能。
